Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation

doi:10.3748/wjg.v16.i20.2468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 20

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5417)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

404

HTML

4530

Figures (1-3)

236

Tables (1-3)

247

Sum=5417

May 28, 2010 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. May 28, 2010; 16(20): 2468-2475
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2468

Full Size Figure Download Figure

Figure 3 Viral suppression, ALT normalization and hepatitis B surface antigen (HBsAg) loss in hepatitis B e antigen (HBeAg)-positive (A) and HBeAg-negative (B) patients after tenofovir disoproxil fumarate (TDF) and adefovir treatment[61]. ¹HBV DNA level of less than 400 copies/mL.

Citation: Jiang L, Yan LN. Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. World J Gastroenterol 2010; 16(20): 2468-2475
URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2468.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2468